UNSPSC 51183305: Saxagliptin anhydrous

This classification denotes an anti-diabetic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8I7IO46IVQ. European Medicines Agency schedules Saxagliptin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB25220. Saxagliptin generally arises in the molecular formula C18H25N3O2.

The term SAXAGLIPTIN is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 19, no. 3, 2005, list 54.) Most nations, for tariff and trade purposes, schedule saxagliptin anhydrous under HS 29339990. As of Q4 2014, SAXAGLIPTIN ANHYDROUS remains US FDA's Preferred Term for this commodity. Saxagliptin anhydrous bears US NLM identifiers UMLS ID C2699273 and NCI Concept Code C75984. SMILES: C1[C@@H]2C[C@@H]2N([C@@H]1C#N)C(=O)[C@H]([C@]34C[C@@H]5CC(C3)C[C@@](C5)(C4)O)N.

UNSPSC 51183305 Saxagliptin anhydrous is a Commodity code representing a specific diabetes medication actively solicited through state and local cooperative purchasing vehicles. State and local governments buy saxagliptin anhydrous primarily as part of broader pharmaceutical procurement programs serving Medicaid beneficiaries, correctional facilities, mental-health institutions, and other publicly funded healthcare systems. The work involves manufacturing and supplying the drug through established wholesale distribution channels with strict compliance requirements around Good Manufacturing Practices, Drug Supply Chain Security Act certification, and FDA approval. Issuing bodies are primarily state departments of health and administration working through multistate cooperative purchasing alliances rather than individual jurisdictions; school districts and smaller municipal entities typically access these drugs indirectly through cooperative agreements rather than direct procurement.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, posted an RFP on January 20, 2026 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities in Minnesota, Oregon, and other member states. Eligible vendors must maintain relationships with at least two of three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—and meet insurance thresholds including $5 million general liability and $2 million network security and privacy liability. Pricing evaluation (75 percent weight) is the dominant factor, with secondary consideration for administrative compliance (5 percent), EDI capability (5 percent), flat pricing contribution (10 percent), and 3 percent administrative fee acceptance (5 percent). Contract awards take effect July 1, 2026, with a two-year initial term and optional extensions at MMCAP's discretion. The RFP does not disclose a specific budget or award value, and no set-aside designations are identified in available materials.